Enhanced mucosal and systemic immune responses to a vaginal vaccine coadministered with RANTES-expressing plasmid DNA using in situ-gelling mucoadhesive delivery system

Vaccine

Volumn 21, Issue 17-18, 2003, Pages 1980-1988

  Oh, Yu Kyoung ^a   Park, Jeong Sook ^b   Yoon, Ho ^a   Kim, Chong Kook ^b  

^a CHA University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Genetic chemokine adjuvant; Hepatitis B surface antigen; In situ gelling mucoadhesive delivery system; Intravaginal immunization

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; PLASMID DNA; POLOXAMER; POLYCARBOPHIL; RANTES; VACCINE;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG POTENCY; DRUG RETENTION; FEMALE; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN PRODUCTION; IN SITU GELLING MUCOADHESIVE DELIVERY SYSTEM; INTERMETHOD COMPARISON; MOUSE; MUCOSA; MUCOSAL IMMUNITY; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALIVA; TISSUE; TITRIMETRY; VAGINA;

EID: 31544441736     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00772-7     Document Type: Article

References (40)

1. Russell M.W., Mestecky J. Humoral immune responses to microbial infections in the genital tract. Microbes Infect. 4(6):2002;667-677.
2. Kozlowski P.A., Cu-Uvin S., Neutra M.R., Flanigan T.P. Mucosal vaccination strategies for women. J. Infect. Dis. 179(Suppl. 3):1999;S493-S498.
3. Schreckenberger C., Sethupathi P., Kanjanahaluethai A., Muller M., Zhou J., Gissmann L.et al. Induction of an HPV 6bL1-specific mucosal IgA response by DNA immunization. Vaccine. 19(2-3):2000;227-233.
4. Ugwoke M.I., Exaud S., Van Den Mooter G., Verbeke N., Kinget R. Bioavailability of apomorphine following intranasal administration of mucoadhesive drug delivery systems in rabbits. Eur. J. Pharm. Sci. 9(2):1999;213-219.
5. Lycke N., Holmgren J. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology. 59(2):1986;301-308.
6. Jertborn M., Svennerholm A.M., Holmgren J. Safety and immunogenicity of an oral recombinant cholera toxin B subunit-whole cell vaccine in Swedish volunteers. Vaccine. 10(2):1992;130-132.
7. Graziano F.M., Cook E.B., Stahl J.L. Cytokines, chemokines, RANTES, and eotaxin. Allergy Asthma Proc. 20(3):1999;141-146.
8. Luther S.A., Cyster J.G. Chemokines as regulators of T cell differentiation. Nat Immunol. 2(2):2001;102-107.
9. Kuna P., Alam R., Ruta U., Gorski P. RANTES induces nasal mucosal inflammation rich in eosinophils, basophils, and lymphocytes in vivo. Am. J. Respir. Crit. Care Med. 157(3 Pt 1):1998;873-879.
10. Lillard J.W. Jr., Boyaka P.N., Taub D.D., McGhee J.R. RANTES potentiates anigen-specific mucosal immune responses. J. Immunol. 166(1):2001;162-169.
11. Xin K.Q., Lu Y., Hamajima K., Fukushima J., Yang J., Inamura K.et al. Immunization of RANTES expression plasmid with a DNA vaccine enhances HIV-1-specific immunity. Clin. Immunol. 92(1):1999;90-96.
12. Chang J.Y., Oh Y.K., Choi H., Kim Y.B., Kim C.K. Rheological evaluation of thermosensitive and mucoadhesive vaginal gels in physiological conditions. Int. J. Pharm. 241(1):2002;155-163.
13. Choi H.G., Oh Y.K., Kim C.K. In situ gelling and mucoadhesive liquid suppository containing acetaminophen: enhanced bioavailability. Int. J. Pharm. 165:1998;23-32.
14. Lane T.E., Liu M.T., Chen B.P.et al. A central role for CD4+ T cells and RANTES in virus-induced central nervous system inflammation and demyelination. J. Virol. 74(3):2000;1415-1424.
15. Mora A.L., Tam J.P. Controlled lipidation and encapsulation of peptides as a useful approach to mucosal immunizations. J. Immunol. 161(7):1998;3616-3623.
16. Gürsel M., Tunca S., Özcengiz G., Alaeddinoglu G. Immunoadjuvant action of plasmid DNA in liposomes. Vaccine. 17(11-12):1999;1376-1383.
17. 2 in healthy women and in women infected with Trichomonas vaginalis: potential implications for metronidazole therapy. Am. J. Obstet. Gynecol. 166(2):1992;620-624.
18. Lehr C.-M. From sticky stuff to sweet receptors-achievements. Eur. J. Drug Metab. Pharmacokinet. 21:1996;139-148.
19. Kunisawa J., Okudaira A., Tsutusmi Y., Takahashi I., Nakanishi T., Kiyono H.et al. Characterization of mucoadhesive microspheres for the induction of mucosal and systemic immune responses. Vaccine. 19(4-5):2000;589-594.
20. Singh M., Briones M., O'Hagan D.T. A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. J. Control Release. 70(3):2001;267-276.
21. Debin A., Kravtzoff R., Santiago J.V.et al. Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses. Vaccine. 20(21-22):2002;2752-2763.
22. Bradney C.P., Sempowski G.D., Liao H.X., Haynes B.F., Staats H.F. Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization. J. Virol. 76(2):2002;517-524.
23. Guerrero R.A., Ball J.M., Krater S.S., Pacheco S.E., Clements J.D., Estes M.K. Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses. J. Virol. 75(20):2001;9713-9722.
24. Hedin L., Olsson B., Diczfalusy M., Flyg C., Petersson A.S., Rosberg S.et al. Intranasal administration of human growth hormone (hGH) in combination with a membrane permeation enhancer in patients with GH deficiency: a pharmacokinetic study. J. Clin. Endocrinol. Metab. 76(4):1993;962-967.
25. Parr E.L., Parr M.B. Immune responses and protection against vaginal infection after nasal or vaginal immunization with attenuated herpes simplex virus type-2. Immunology. 98(4):1999;639-645.
26. Kozlowski P.A., Williams S.B., Lynch R.M., Flanigan T.P., Patterson R.R., Cu-Uvin S.et al. Differential induction of mucosal and systemic antibody responses in women after nasal, rectal, or vaginal immunization: influence of the menstrual cycle. J. Immunol. 169(1):2002;566-574.
27. Lehner T. The role of CCR5 chemokine ligands and antibodies to CCR5 coreceptors in preventing HIV infection. Trends Immunol. 23(7):2002;347-351.
28. Cairns J.S., D'Souza M.P. Chemokines and HIV-1 second receptors: the therapeutic connection. Nat. Med. 4(5):1998;563-568.
29. Appay V., Rowland-Jones S.L. RANTES: a versatile and controversial chemokine. Trends Immunol. 22(2):2001;83-87.
30. Beck L.A., Dalke S., Leiferman K.M., Bickel C.A., Hamilton R., Rosen H.et al. Cutaneous injection of RANTES causes eosinophil recruitment: comparison of non-allergic and allergic human subjects. J. Immunol. 159(6):1997;2962-2972.
31. Youssef S., Maor G., Wildbaum G., Grabie N., Gour-Lavie A., Karin N. C-C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis. J. Clin. Invest. 106(3):2000;361-371.
32. Haneberg B., Dalseg R., Oftung F.et al. Towards a nasal vaccine against meningococcal disease, and prospects for its use as a mucosal adjuvant. Dev. Biol. Stand. 92:1998;127-133.
33. Kato H., Bukawa H., Hagiwara E.et al. Rectal and vaginal immunization with a macromolecular multicomponent peptide vaccine candidate for HIV-1 infection induces HIV-specific protective immune responses. Vaccine. 18(13):2000;1151-1160.
34. Isaka M., Yasuda Y., Kozuka S.et al. Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant. Vaccine. 18(7-8):1999;43-51.
35. Fujihashi K., Koga T., van Ginkel F.W., Hagiwara Y., McGhee J.R. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine. 20(19-20):2002;2431-2438.
36. Bagley K.C., Abdelwahab S.F., Tuskan R.G., Fouts T.R., Lewis G.K. Cholera toxin and heat-labile enterotoxin activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cyclic AMP-dependent pathway. Infect. Immun. 70(10):2002;5533-5539.
37. Gagliardi M.C., Sallusto F., Marinaro M., Vendetti S., Riccomi A., De Magistris M.T. Effects of the adjuvant cholera toxin on dendritic cells: stimulatory and inhibitory signals that result in the amplification of immune responses. Int. J. Med. Microbiol. 291(6-7):2002;571-575.
38. Hamajima K., Hoshino Y., Xin K.Q., Hayashi F., Tadokoro K., Okuda K. Systemic and mucosal immune responses in mice after rectal and vaginal immunization with HIV-DNA vaccine. Clin. Immunol. 102(1):2002;12-18.
39. Ismail F.A., Napaporn J., Hughes J.A., Brazeau G.A. In situ gel formulations for gene delivery: release and myotoxicity studies. Pharm. Dev. Technol. 5(3):2000;391-397.
40. Park J.S., Oh Y.K., Yoon H., Kim J.M., Kim C.K. In situ gelling and mucoadhesive polymer vehicles for controlled intranasal delivery of plasmid DNA. J. Biomed. Mater. Res. 59(1):2002;144-151.